17: Stroke and Cerebrovascular Disease

Key Points

• Disease summary:

  • Stroke is an umbrella term for the rapid loss of neurologic function in a particular vascular territory, with symptoms lasting greater than 24 hours.

  • The causes of stroke are broadly defined as either ischemic or hemorrhagic.

  • Clinical manifestations depend on the vascular territory affected, with the middle cerebral artery (MCA) being most commonly affected.

  • Management of stroke involves identifying the onset and duration of symptoms, assessing and maintaining normal vital signs, evaluating whether the patient with acute stroke is a candidate for thrombolysis, and longer-term risk factor management.

• Differential diagnosis for stroke:

  • Several phenomena may present similar to stroke, including transient ischemic attacks ([TIAs], which manifest as neurologic deficits lasting <24 hours), migraines, Todd paresis, head trauma, brain tumors, and metabolic and/or toxic insults (such as hypoglycemia, hypothyroidism, renal or liver failure, certain drug intoxications).

• Monogenic forms:

  • Monogenic forms of stroke include (1) syndromes that feature ischemic or hemorrhagic stroke as the primary or key component, or (2) multisystem syndromes or conditions that contain stroke as a secondary component.

• Family history:

  • A family history of early cardiovascular disease increases the likelihood for the development of ischemic stroke. A family history of cerebral aneurysms may be relevant for hemorrhagic stroke risk.

• Environmental factors:

  • For ischemic stroke, the classical determinants of atherosclerosis, such as smoking, poor diet, obesity, hyperlipidemia, and hypertension can increase the risk for stroke, as can the use of certain medications, such as hormone replacement therapy.

• Genome-wide association studies (GWAS):

  • GWAS findings of stroke as a clinical end point are relatively inconsistent, while GWAS of risk factors and intermediate traits, such as plasma lipids and hypertension, show much more consistency across studies.

• Pharmacogenomics:

  • Preventive therapies for embolic stroke, specifically Coumadin (warfarin), show replicable associations with interindividual genomic variation. Also, interindividual differences in the susceptibility to serious side effects from statins, used widely in stroke prevention, appear to have a genetic basis.

Diagnostic Criteria and Clinical Characteristics

Diagnostic Criteria

Stroke is defined as the rapid loss of neurologic function in a particular vascular territory caused by either ischemia or hemorrhage, with symptoms lasting greater than 24 hours. Ischemic strokes can be subdivided according to cause: thrombotic or embolic. Meanwhile, hemorrhagic strokes are subdivided according to location of bleeding: parenchymal (intracerebral hemorrhage [ICH]) or subarachnoid hemorrhage (SAH) (Fig. 17-1). The diagnosis of stroke depends on accurate history and physical examination, and confirmed by appropriate neuroimaging.

Clinical Characteristics

The exact clinical characteristics of a stroke depend on the vascular territory affected, with the MCA most often affected. See Fig. 17-2 for types of vessels affected and their respective clinical characteristics.